Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Protalix BioTherapeutics (PLX) over the last 15 years, with Q2 2025 value amounting to $4.1 million.

  • Protalix BioTherapeutics' Cash from Financing Activities changed N/A to $4.1 million in Q2 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year change of. This contributed to the annual value of -$16.8 million for FY2024, which is 16808.56% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Cash from Financing Activities of $4.1 million as of Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Cash from Financing Activities peaked at $42.1 million during Q1 2021, and registered a low of -$26.0 million during Q3 2021.
  • In the last 5 years, Protalix BioTherapeutics' Cash from Financing Activities had a median value of $4.1 million in 2022 and averaged $5.5 million.
  • In the last 5 years, Protalix BioTherapeutics' Cash from Financing Activities tumbled by 68117.17% in 2021 and then surged by 20071.68% in 2022.
  • Protalix BioTherapeutics' Cash from Financing Activities (Quarter) stood at -$4.0 million in 2021, then skyrocketed by 200.72% to $4.1 million in 2022, then skyrocketed by 156.02% to $10.4 million in 2023, then crashed by 65.24% to $3.6 million in 2024, then rose by 13.18% to $4.1 million in 2025.
  • Its Cash from Financing Activities stands at $4.1 million for Q2 2025, versus $5.1 million for Q1 2025 and $3.6 million for Q4 2024.